Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 5 years, the highest 3-Year average Book Value per Share Growth Rate of Ensysce Biosciences was 88.10% per year. The lowest was 88.10% per year. And the median was 88.10% per year.
Competitive Comparison of Ensysce Biosciences's 3-Year Book Growth Rate
For the Biotechnology subindustry, Ensysce Biosciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensysce Biosciences's 3-Year Book Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Ensysce Biosciences's 3-Year Book Growth Rate falls into.
Ensysce Biosciences 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Ensysce Biosciences (NAS:ENSC) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Ensysce Biosciences 3-Year Book Growth Rate Related Terms
Thank you for viewing the detailed overview of Ensysce Biosciences's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENSC has been successfully added to your